Multigrain Food Glycemic Index (GI) Evaluation: Standards, Testing Methods, and Applications

Multigrain food GI evaluation measures the postprandial blood glucose response of whole grain and mixed cereal products, providing essential scientific data for product development, nutritional claims, and low-GI certification. Performed in accordance with ISO 26642:2010 and related national standards, this evaluation combines standardized human clinical trials with in vitro digestion analysis to deliver accurate and internationally recognized GI classification. This article details the technical framework, sample requirements, testing protocols, quality control measures, and practical applications of GI evaluation for multigrain foods.

Technical Overview

The glycemic index (GI) is a relative ranking of carbohydrate-containing foods based on their ability to raise blood glucose levels after consumption, expressed on a scale where pure glucose equals 100. Multigrain foods—products formulated from two or more whole grains, pseudocereals, or legumes such as oats, buckwheat, millet, sorghum, quinoa, brown rice, corn, adzuki beans, and mung beans—exhibit wide variability in glycemic response depending on their composition, formulation, and processing conditions. Because multigrain products are frequently marketed as healthier carbohydrate choices, objective GI evaluation is essential to substantiate such claims.

According to internationally accepted classification criteria:

• Low GI: value of 55 or below
• Medium GI: value between 56 and 69
• High GI: value of 70 or above

The principal reference standard for GI determination is ISO 26642:2010 (Food products — Determination of the glycaemic index (GI) and recommendation for food classification), which defines the clinical protocol, subject requirements, reference food specifications, and calculation methodology. In China, WS/T 652-2019 (Determination method of food glycemic index) provides the corresponding national health industry framework. Key factors influencing the GI of multigrain foods include amylose-to-amylopectin ratio, dietary fiber content, particle size, degree of starch gelatinization, resistant starch formation, thermal processing intensity, and the physical integrity of the food matrix.

Testing Samples

Raw Multigrain Ingredients

Individual whole grains, pseudocereals, and legumes submitted for baseline glycemic characterization. Typical samples include oat groats, buckwheat, proso millet, foxtail millet, sorghum, quinoa, barley, brown rice, black rice, corn, chickpeas, red beans, mung beans, and kidney beans. Representative sampling and documentation of variety, origin, and harvest batch are required for reproducible results.

Multigrain Flour Blends and Premixes

Composite flours and formulated dry mixes intended for porridge, baking, or extrusion. Because milling fineness and blending ratio significantly affect starch accessibility, samples must be submitted in their final commercial formulation along with preparation instructions.

Cooked and Ready-to-Eat Multigrain Products

Finished foods tested under standardized preparation conditions, including multigrain porridge, mixed grain rice, whole wheat and multigrain bread, multigrain noodles and pasta, breakfast cereals, granola, cereal bars, biscuits, crackers, and steamed grain-based products. These samples reflect the glycemic impact of the product as actually consumed.

Multigrain-Based Functional and Nutritional Foods

Meal replacement powders, diabetic-friendly formula foods, senior nutrition products, and fortified multigrain beverages where low-GI performance is a primary product claim requiring verification.

Testing Items

A comprehensive GI evaluation program for multigrain foods typically encompasses the following analytical parameters:

• Glycemic Index (GI) — full clinical determination against a glucose reference
• Glycemic Load (GL) — calculated per serving based on GI and available carbohydrate content
• Available (glycemic) carbohydrate content — prerequisite for test portion calculation
• In vitro starch digestibility — rapidly digestible starch (RDS), slowly digestible starch (SDS), and resistant starch (RS)
• Rate of in vitro glucose release and digestion kinetic profiling
• Total, soluble, and insoluble dietary fiber
• Amylose and amylopectin content
• Macronutrient characterization — moisture, protein, fat, and total starch
• Insulinemic response (optional extended protocol) — incremental insulin area under the curve and insulinemic index

These combined items allow correlation between compositional characteristics, digestion behavior, and in vivo glycemic outcome, supporting both regulatory claims and formulation optimization.

Testing Methods

In Vivo Clinical GI Determination (Primary Method)

The internationally recognized method follows ISO 26642:2010 and WS/T 652-2019 using a randomized, double-measurement crossover design with healthy human subjects. The core protocol includes:

• Subject recruitment of at least 10 qualified volunteers with normal fasting glucose and normal glucose tolerance, verified by screening; all subjects provide informed consent under an ethically approved protocol
• Reference testing with a 50 g anhydrous glucose solution dissolved in water, tested on at least two separate occasions to establish the reference response
• Test food administration containing exactly 50 g available carbohydrate, calculated from analytically determined carbohydrate composition
• Capillary blood sampling at fasting baseline and at 15, 30, 45, 60, 90, and 120 minutes after consumption, using validated glucose oxidase-based analytical methods
• Calculation of the incremental area under the blood glucose response curve (IAUC), ignoring any area beneath the baseline
• GI computation as the ratio of the test food IAUC to the mean reference IAUC, multiplied by 100, with results expressed as mean ± SEM and coefficient of variation reported for data transparency

In Vitro Starch Digestion Analysis (Screening and Support Method)

In vitro enzymatic digestion models simulate oral, gastric, and small intestinal phases using amylase, pepsin, and pancreatic enzyme preparations under controlled pH and temperature. Timed sampling quantifies released glucose, generating digestion curves from which RDS, SDS, and RS fractions are derived. The hydrothermal index and expected glycemic index (eGI) can be estimated from first-order kinetic constants. While in vitro methods cannot replace clinical measurement for labeling purposes, they provide cost-effective screening for formulation development and enable mechanistic interpretation of processing effects.

Glycemic Load Determination

Glycemic load integrates GI with portion size and is calculated as GI multiplied by grams of available carbohydrate per serving, divided by 100. GL classification thresholds are: low GL ≤ 10, medium GL 11–19, and high GL ≥ 20 per serving. GL data are frequently requested alongside GI for nutrition labeling and dietary guidance documentation.

Quality Assurance and Data Validity

All testing is performed by accredited third-party laboratories under ISO/IEC 17025 quality management systems. Critical quality controls include:

• Verification of subject compliance with pre-test fasting and physical activity restrictions
• Randomization of test sequences with adequate washout periods of at least 24 to 48 hours between sessions
• Duplicate reference food testing with acceptance criteria for intra-individual variability
• Use of certified reference materials and calibrated glucose analyzers
• Statistical outlier assessment and transparent reporting of between-subject variability

Applications

GI evaluation of multigrain foods serves multiple technical and commercial objectives:

• Low-GI product certification and label claim substantiation for retail and e-commerce platforms that require third-party clinical evidence
• Research and development support for reformulating multigrain blends, optimizing processing parameters such as extrusion temperature and retrogradation treatment to lower glycemic response
• Clinical and dietary guidance materials for diabetes management, weight control programs, and sports nutrition, where low-GI carbohydrate selection is clinically recommended
• Regulatory compliance and market access documentation for products sold in jurisdictions recognizing GI claims, including submission to low-GI certification schemes
• Comparative benchmarking against competitor products and conventional refined-grain equivalents for marketing and scientific communication
• Academic research and publication on the metabolic effects of whole grain and legume-based food matrices

FAQ

What is the difference between GI and GL?

GI measures the quality of a carbohydrate source by ranking its blood glucose impact relative to glucose, while glycemic load combines GI with the actual amount of available carbohydrate in a serving, reflecting both quality and quantity. A multigrain food can have a moderate GI but a low GL if consumed in small portions with limited carbohydrate content.

Can GI be predicted accurately without human testing?

In vitro digestion models provide useful screening estimates and mechanistic insight, but internationally recognized GI values used for labeling and certification must be determined through standardized clinical testing per ISO 26642:2010, because individual metabolic responses and food matrix effects cannot be fully replicated in laboratory simulation.

How many human subjects are required, and how long does testing take?

ISO 26642:2010 specifies a minimum of 10 eligible subjects, and accredited third-party laboratories often enroll 12 or more to strengthen statistical power. A complete study including screening, reference sessions, and test sessions typically requires 4 to 8 weeks, depending on the number of samples submitted in parallel.

Why do identically formulated multigrain products sometimes show different GI values?

Processing variables such as milling particle size, gelatinization degree, cooling-induced retrogradation, extrusion intensity, and cooking time alter starch digestibility substantially. Even small changes in hydrothermal treatment can shift GI by 10 to 20 points, which is why finished products should be tested in their final consumable form.

What sample quantity should be submitted for evaluation?

Typical requirements include sufficient product to supply each subject with portions containing 50 g available carbohydrate across all test sessions, generally 2 to 5 kg for finished foods, plus additional material for compositional analysis of moisture, starch, fiber, and available carbohydrate. Exact quantities are confirmed during the pre-test consultation with the laboratory.

Is an ethical approval necessary for GI testing?

Yes. Clinical GI studies involving human subjects must be reviewed and approved by an independent ethics committee, and all volunteers must provide written informed consent before participation, in line with the principles of the Declaration of Helsinki and applicable national regulations.